Navigation Links
A Novel Treatment for KSHV-infected Lymphomas

Kaposi’s sarcoma herpesvirus (KSHV) is a human tumor virus which causes Kaposi’s sarcoma and primary// effusion lymphoma (PEL).

PELs are aggressive lymphomas with reported median survival time less than six months after diagnosis.

Researchers at the University of Helsinki have discovered that activation of the p53 pathway offers a novel effective treatment modality for KSHV-infected lymphomas.

The findings by the research group of Dr. P?ivi Ojala (University of Helsinki) in collaboration with the groups of Professor Marikki Laiho (University of Helsinki), Dr. Pirjo Laakkonen (University of Helsinki), and Dr. Jürgen Haas (Max von Pettenkofer Institute, Munich & University of Edinburgh) open new options for exploiting reactivation of p53 as a novel and highly selective treatment modality for this virally-induced lymphoma.

The project involves scientists from two Academy of Finland National Centre of Excellence Programs, the Translational Genome-Scale Biology and Cancer Biology. The study will be published 15.3.2007 in the Journal of Clinical Investigation.

TP53 gene encodes a transcription factor (p53) that plays a central role in protecting cells from tumor development by inducing cell-cycle arrest or apoptosis via a complex signal transduction network referred to as the p53 pathway. TP53 gene is mutated or deleted in 50% of all malignant tumors.

A recently discovered strategy for p53 activation targets the interaction of p53 with its negative regulator MDM2. This is based on a potent and selective small-molecule inhibitor of the p53–MDM2 interaction, the Nutlin-3a, originally discovered by Dr Lyubomir T Vassilev (Roche Research Center, Nutley, NJ., USA). Nutlin-3a has been suggested to be a potential treatment option for cancers with wt p53.

PEL is a non-Hodgkin type lymphoma latently infected with KSHV, and it manifests as an effusion malignancy in Kaposi’s sarcoma patients. Ther
'"/>




Page: 1 2

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
(Date:7/25/2008)...er & Olsen LLP has filed a,class action lawsuit ag..."Company") (Nasdaq: ARTC ) and certain of its off...istrict of Texas on behalf of all persons or,entit... January 24, 2008,through July 18, 2008 (the "Comm...or entities who purchased call options or sold put...
(Date:7/25/2008)... therapy may be due to genetic factors , ... challenges the long-held belief that the hepatiti...y to restore itself after HIV patients are treated.... , From 50 percent to 90 percent of HIV-infect...ous drug use is the main cause of both types of in...
(Date:7/25/2008)...ity.com announces the,availability of Trade Alerts... all of the daily trading notes for free by visiti...erts include: DUSA Pharmaceuticals Inc. (Nasdaq: ... MBRK ), NovaMed Inc. (Nasdaq:,NOVA), Adolor Corp....) and,Abaxis Inc. (Nasdaq: ABAX )., Join investo...
(Date:7/25/2008)...mprovements in Members, Health, ATLANTA, July 25 ...h,care quality management solutions for health pla...nto a long-term agreement with Wellmark, Inc. to,c...lity(SM) Incent and,Reward Best Practices initiati...are clinicians to promote improved quality health ...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...a spectacle when she had epileptic seizures, almos... her fit//, her face had a scowl and a guttural si...she convulsed. This had led her to be named as "T...en Schneider, of Schneider Children's Hospital in ...
...n recommended for medical conditions such as endom...estyle choice for women who dislike menstruation o...sion safe and is it a reasonable lifestyle choice,... Psychologist in this week’s BMJ? Birth control o...
... with lethal and disabling conditions is illegal w...ctice vary between different countries. An edito...e? In the Netherlands, about 200,000 live births ...0-20 babies – mostly with severe congenital malfor...
...roats may benefit from having a tonsillectomy in t... is// still unclear, and any benefits have to be b... A small study of adults from Finland showed tha...the likelihood of further infection after 90 days,...
Other Medicine News:Health News:Should Menstrual Suppression Be a Lifestyle Choice? 2Health News:Should the UK Adopt Dutch Rules on Euthanasia in Newborn Babies? 2Health News:Is It Worth Having Surgery to Remove Your Tonsils? 2
(Date:7/22/2008)...- Strong efficacy results from a multi-center 293-...com , Toronto Stock Exchange Symbol: CYT, MONTRE...echnologies,Inc., the global leader in cryotherapy...unced that results previously presented from three...roduct, Arctic Front(R),were published earlier to...
(Date:7/22/2008)...tudy Demonstrates Feasibility and Efficacy of Trea...y Liver Cancer, SAN FRANCISCO, and YONGIN-SI, Sou...San Francisco, CA and Ottawa, Ontario), and its So...day that novel findings from,a Phase I clinical tr...nstrated that the product was well-tolerated and r...
(Date:7/22/2008)...SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/ ...t it has completed patient enrollment,in its Phase...bility and,ammonia scavenging effects of HPN-100 (...henylbutyrate) in patients with urea cycle disorde...esults in the fourth quarter,of this year., (Logo...
(Date:7/22/2008)...SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-Firs...nnounced it has successfully completed the,enrollm...olled hypertension,in two clinical pharmacology st...y announced timelines. These trials are designed t..., in comparison to ibuprofen and,naproxen, using t...
Breaking Medicine Technology:CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Nightingale announces US 2412 3 million sale of its Therapist Helper business 13183 1Nightingale announces US 2412 3 million sale of its Therapist Helper business 13183 2Nightingale announces US 2412 3 million sale of its Therapist Helper business 13183 3Nightingale announces US 2412 3 million sale of its Therapist Helper business 13183 4Congressman Walberg Awarded for Protecting Medicare Choices 13181 1Two Faced Particles Act Like Tiny Submarines 3636 1Two Faced Particles Act Like Tiny Submarines 3636 2Two Faced Particles Act Like Tiny Submarines 3636 3Computer simulations point to key molecular basis of cystic fibrosis 2364 1Computer simulations point to key molecular basis of cystic fibrosis 2364 2
...tatistically Significant Clinical Results for,SB-5...athy, CHICAGO, June 22, 2007 /PRNewswire-FirstCall... presentation of encouraging,Phase 1 clinical data...Scientific Sessions of the American Diabetes Assoc... entitled, "Improved,Neurologic Exam and Nerve Con...
... Symptoms Negatively Affect Relationship, BOCA RAT... a new,nationwide survey show that more than half ...dical condition known as low,testosterone incorrec...The survey also found that, while women believe th...gatively impact their,relationship, treatment of t...
Other Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 9New Poll Shows Men, Women Incorrectly Blame Symptoms of Low,Testosterone on Normal Aging 2New Poll Shows Men, Women Incorrectly Blame Symptoms of Low,Testosterone on Normal Aging 3New Poll Shows Men, Women Incorrectly Blame Symptoms of Low,Testosterone on Normal Aging 4New Poll Shows Men, Women Incorrectly Blame Symptoms of Low,Testosterone on Normal Aging 5
Specially designed for rugged use; perfect tool with power and endurance. Balance of weight and power helps reduce user fatigue. Internally lubricated for longer serivce. Switch is designed and place
De Soutter supply clean cast removal saws that are low in voltage and contain an integrated extractor system, combining state-of-the-art ergonomics with performance and durability.
...he osteotomy staples is quite similar to the type ...e the inner position of the anti recoil contours a...lique staples). There are 3 kinds of staples: 1.... staples can have 3 different widths: 20mm, 26 mm ...
...e Barium Sulfate USP is specifically designed to p...pabilities for todays medical professionals who ad...y. Comprised of a uniform particle size, Biotrace ...lting in a consistent visualization of bone cement...
Medicine Products: